The emerging roles of YAP and TAZ in cancer

Nature Reviews Cancer

Volumn 15, Issue 2, 2015, Pages 73-79

  Moroishi, Toshiro ^a   Hansen, Carsten Gram ^a   Guan, Kun Liang ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MICRORNA; PEPTIDE; PROTEIN; TRANSCRIPTIONAL COACTIVATOR WITH PDZ BINDING MOTIF; UNCLASSIFIED DRUG; VERTEPORFIN; VESTIGIAL LIKE FAMILY MEMBER 4; YES ASSOCIATED PROTEIN; APC2 PROTEIN, HUMAN; CYTOSKELETON PROTEIN; GNA11 PROTEIN, HUMAN; GNAQ PROTEIN, HUMAN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; HIPPO PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHOPROTEIN; PROTEIN SERINE THREONINE KINASE; RAS PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; STK11 PROTEIN, HUMAN; TAZ PROTEIN, HUMAN; TRANSCRIPTION FACTOR; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BIOGENESIS; CANCER GROWTH; COLON POLYPOSIS; DNA DAMAGE; G ALPHA 11 GENE; G ALPHA Q GENE; GENE; GENE ACTIVATION; GENE MUTATION; HOMEOSTASIS; HUMAN; NEOPLASM; ONCOGENE K RAS; ORGAN SIZE; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY; CELL TRANSFORMATION; GENETICS; METABOLISM;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; CYTOSKELETAL PROTEINS; GTP-BINDING PROTEIN ALPHA SUBUNITS; HUMANS; MICRORNAS; NEOPLASMS; PHOSPHOPROTEINS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TRANSCRIPTION FACTORS; WNT SIGNALING PATHWAY;

EID: 84923183206     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3876     Document Type: Article

References (65)

1. Pan, D. The Hippo signaling pathway in development and cancer. Dev. Cell 19, 491-505 (2010).
2. Harvey, K. F., Zhang, X. & Thomas, D. M. The Hippo pathway and human cancer. Nature Rev. Cancer 13, 246-257 (2013).
3. Mo, J. S., Park, H. W. & Guan, K. L. The Hippo signaling pathway in stem cell biology and cancer. EMBO Rep. 15, 642-656 (2014).
4. Johnson, R. & Halder, G. The two faces of Hippo: Targeting the Hippo pathway for regenerative medicine and cancer treatment. Nature Rev. Drug Discov. 13, 63-79 (2014).
5. Nishioka, N. et al. The Hippo signaling pathway components LATS and YAP pattern TEAD4 activity to distinguish mouse trophectoderm from inner cell mass. Dev. Cell 16, 398-410 (2009).
6. Xin, M. et al. Hippo pathway effector YAP promotes cardiac regeneration. Proc. Natl Acad. Sci. USA 110, 13839-13844 (2013).
7. Varelas, X. The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease. Development 141, 1614-1626 (2014).
8. Calvo, F. et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nature Cell Biol. 15, 637-646 (2013).
9. Zhang, J. et al. YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nature Cell Biol. 11, 1444-1450 (2009).
10. Fujii, M. et al. TGF? synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth. J. Exp. Med. 209, 479-494 (2012).
11. Aragona, M. et al. A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. Cell 154, 1047-1059 (2013).
12. Dupont, S. et al. Role of YAP/TAZ in mechanotransduction. Nature 474, 179-183 (2011).
13. Friedl, P. & Alexander, S. Cancer invasion and the microenvironment: Plasticity and reciprocity. Cell 147, 992-1009 (2011).
14. Tang, Y. et al. MT1-MMP-dependent control of skeletal stem cell commitment via a ?1-integrin/YAP/TAZ signaling axis. Dev. Cell 25, 402-416 (2013).
15. Zhao, B. et al. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev. 26, 54-68 (2012).
16. Codelia, V. A., Sun, G. & Irvine, K. D. Regulation of YAP by mechanical strain through JNK and Hippo signaling. Curr. Biol. 24, 2012-2017 (2014).
17. Yu, F. X. et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 150, 780-791 (2012).
18. Zhao, B. et al. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev. 25, 51-63 (2011).
19. Adler, J. J. et al. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases. Proc. Natl Acad. Sci. USA 110, 17368-17373 (2013).
20. O'Hayre, M. et al. The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nature Rev. Cancer 13, 412-424 (2013).
21. Chen, D. et al. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nature Med. 18, 1511-1517 (2012).
22. Fan, R., Kim, N. G. & Gumbiner, B. M. Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1. Proc. Natl Acad. Sci. USA 110, 2569-2574 (2013).
23. Azzolin, L. et al. YAP/TAZ incorporation in the ?-Catenin destruction complex orchestrates the WNT response. Cell 158, 157-170 (2014).
24. Barry, E. R. et al. Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature 493, 106-110 (2013).
25. Heallen, T. et al. Hippo pathway inhibits WNT signaling to restrain cardiomyocyte proliferation and heart size. Science 332, 458-461 (2011).
26. Rosenbluh, J. et al. ?-catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 151, 1457-1473 (2012).
27. Varelas, X. et al. The Hippo pathway regulates WNT/?-catenin signaling. Dev. Cell 18, 579-591 (2010).
28. Varelas, X. et al. TAZ controls SMAD nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. Nature Cell Biol. 10, 837-848 (2008).
29. Alarcon, C. et al. Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF? pathways. Cell 139, 757-769 (2009).
30. Attisano, L. & Wrana, J. L. Signal integration in TGF?, WNT, and Hippo pathways. F1000Prime Rep. 5, 17 (2013).
31. Kumar, M. S., Lu, J., Mercer, K. L., Golub, T. R. & Jacks, T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nature Genet. 39, 673-677 (2007).
32. Mori, M. et al. Hippo signaling regulates microprocessor and links cell-density-dependent miRNA biogenesis to cancer. Cell 156, 893-906 (2014).
33. Zhao, B. et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 21, 2747-2761 (2007).
34. Chaulk, S. G., Lattanzi, V. J., Hiemer, S. E., Fahlman, R. P. & Varelas, X. The Hippo pathway effectors TAZ/YAP regulate dicer expression and microRNA biogenesis through Let-7. J. Biol. Chem. 289, 1886-1891 (2014).
35. Hong, J. H. et al. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 309, 1074-1078 (2005).
36. Cordenonsi, M. et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 147, 759-772 (2011).
37. Skibinski, A. et al. The Hippo transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitment. Cell Rep. 6, 1059-1072 (2014).
38. Yimlamai, D. et al. Hippo pathway activity influences liver cell fate. Cell 157, 1324-1338 (2014).
39. Chan, S. W. et al. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res. 68, 2592-2598 (2008).
40. Reginensi, A. et al. YAP-and CDC42-dependent nephrogenesis and morphogenesis during mouse kidney development. PLoS Genet. 9, e1003380 (2013).
41. Zhang, N. et al. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev. Cell 19, 27-38 (2010).
42. Liu-Chittenden, Y. et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 26, 1300-1305 (2012).
43. Zhang, W. et al. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci. Signal. 7, ra42 (2014).
44. Kapoor, A. et al. YAP1 activation enables bypass of oncogenic kras addiction in pancreatic cancer. Cell 158, 185-197 (2014).
45. Shao, D. D. et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 158, 171-184 (2014).
46. Shackelford, D. B. & Shaw, R. J. The LKB1-AMPK pathway: Metabolism and growth control in tumour suppression. Nature Rev. Cancer 9, 563-575 (2009).
47. Mohseni, M. et al. A genetic screen identifies an LKB1-MARK signalling axis controlling the Hippo-YAP pathway. Nature Cell Biol. 16, 108-117 (2014).
48. Tumaneng, K. et al. YAP mediates crosstalk between the Hippo and PI(3)K-TOR pathways by suppressing PTEN via miR-29. Nature Cell Biol. 14, 1322-1329 (2012).
49. Feng, X. et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell 25, 831-845 (2014).
50. Yu, F. X. et al. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell 25, 822-830 (2014).
51. Wang, L. et al. Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells. PLoS ONE 8, e65539 (2013).
52. Liu, G. et al. Kaposi sarcoma-associated herpesvirus promotes tumorigenesis by modulating the Hippo pathway. Oncogene http://dx.doi.org/10.1038/onc.2014.281 (2014).
53. Nguyen, H. T. et al. Viral small T oncoproteins transform cells by alleviating Hippo-pathway-mediated inhibition of the YAP proto-oncogene. Cell Rep. 8, 707-713 (2014).
54. Imajo, M., Miyatake, K., Iimura, A., Miyamoto, A. & Nishida, E. A molecular mechanism that links Hippo signalling to the inhibition of WNT/?-catenin signalling. EMBO J. 31, 1109-1122 (2012).
55. Levy, D., Adamovich, Y., Reuven, N. & Shaul, Y. YAP1 phosphorylation by c-ABL is a critical step in selective activation of proapoptotic genes in response to DNA damage. Mol. Cell 29, 350-361 (2008).
56. Cottini, F. et al. Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nature Med. 20, 599-606 (2014).
57. Yoo, H. Y. et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nature Genet. 46, 371-375 (2014).
58. Koontz, L. M. et al. The Hippo effector Yorkie controls normal tissue growth by antagonizing scalloped-mediated default repression. Dev. Cell 25, 388-401 (2013).
59. Jiao, S. et al. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell 25, 166-180 (2014).
60. Sorrentino, G. et al. Metabolic control of YAP and TAZ by the mevalonate pathway. Nature Cell Biol. 16, 357-366 (2014).
61. Wang, Z. et al. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proc. Natl Acad. Sci. USA 111, E89-E98 (2014).
62. Gronich, N. & Rennert, G. Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates. Nature Rev. Clin. Oncol. 10, 625-642 (2013).
63. Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333-339 (2013).
64. Nguyen, H. B., Babcock, J. T., Wells, C. D. & Quilliam, L. A. LKB1 tumor suppressor regulates AMP kinase/mTOR-independent cell growth and proliferation via the phosphorylation of YAP. Oncogene 32, 4100-4109 (2013).
65. Moya, I. M. & Halder, G. Discovering the Hippo pathway protein-protein interactome. Cell Res. 24, 137-138 (2014).